All In Biotech

Drug Trial Radar · NCT05517421

Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants With Active Thyroid Eye Disease (TED)

Last checked: Nov 19, 2026Latest source record: Dec 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 114 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

114

Actual

Start

Nov 23, 2022

Primary completion

Nov 2, 2025

Study completion Nov 18, 2025

Sponsor

Lead sponsor
Immunovant Sciences GmbHIndustry
Sponsor type
Industry
First posted
Aug 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.

Conditions

  • Thyroid Eye Disease

Interventions

  • BatoclimabDrug

    Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody

  • PlaceboDrug

    Matching Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of proptosis respondersTime frame: At Week 24

Locations

93 sites in 9 countries. Site status is shown where the registry gives one.

  • Site Number - 1557

    Beverly Hills, California

  • Site Number - 1539

    Carlsbad, California

  • Site Number - 1502

    Los Angeles, California

  • Site Number - 1505

    Los Angeles, California

  • Site Number - 1532

    Los Angeles, California

  • Site Number - 1537

    San Diego, California

  • Site Number - 1531

    Torrance, California

  • Site Number - 1501

    Aurora, Colorado

  • Site Number - 1544

    Longmont, Colorado

  • Site Number - 1547

    Newark, Delaware

  • Site Number - 1504

    Miami, Florida

  • Site Number - 1538

    Port Charlotte, Florida

  • Site Number - 1542

    Tampa, Florida

  • Site Number - 1536

    West Palm Beach, Florida

  • Site Number - 1554

    Stockbridge, Georgia

  • Site Number - 1534

    Chicago, Illinois

  • Site Number - 1545

    Iowa City, Iowa

  • Site Number - 1535

    Baltimore, Maryland

  • Site Number - 1506

    Boston, Massachusetts

  • Site Number - 1540

    Las Vegas, Nevada

  • Site Number - 1530

    Chapel Hill, North Carolina

  • Site Number - 1550

    Columbus, Ohio

  • Site Number - 1507

    Portland, Oregon

  • Site Number - 1556

    Warwick, Rhode Island

  • Site Number - 1551

    Dallas, Texas

  • Site Number - 1508

    Houston, Texas

  • Site Number - 1558

    Mesquite, Texas

  • Site Number - 1500

    Roanoke, Virginia

  • Site Number - 1509

    Madison, Wisconsin

  • Site Number - 2502

    Edmonton, Alberta, Canada

  • Site Number - 2500

    Ottawa, Ontario, Canada

  • Site Number - 2501

    Montreal, Quebec, Canada

  • Site Number - 3452

    Tbilisi, Georgia

  • Site Number - 3454

    Tbilisi, Georgia

  • Site Number - 3455

    Tbilisi, Georgia

  • Site Number - 3450

    Tbilisi, Georgia

  • Site Number - 3451

    Tbilisi, Georgia

  • Site Number - 3453

    Tbilisi, Georgia

  • Site Number - 6611

    Schwerin, Germany

  • Site Number - 6609

    Tübingen, Baden - Wuttemberg, Germany

Showing 40 of 93 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.